BRPI0912570B8 - anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos - Google Patents

anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos

Info

Publication number
BRPI0912570B8
BRPI0912570B8 BRPI0912570A BRPI0912570A BRPI0912570B8 BR PI0912570 B8 BRPI0912570 B8 BR PI0912570B8 BR PI0912570 A BRPI0912570 A BR PI0912570A BR PI0912570 A BRPI0912570 A BR PI0912570A BR PI0912570 B8 BRPI0912570 B8 BR PI0912570B8
Authority
BR
Brazil
Prior art keywords
ifn
humanized anti
antigen
binding fragment
therapeutic composition
Prior art date
Application number
BRPI0912570A
Other languages
English (en)
Portuguese (pt)
Inventor
Olsen Krogh Berit
Friedrichsen Birgitte
Lund Pedersen Inger
Fleckner Jan
Anders Svensson Lars
Padkjaer Soren
Original Assignee
Argos Therapeutics Inc
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc, Novo Nordisk As filed Critical Argos Therapeutics Inc
Publication of BRPI0912570A2 publication Critical patent/BRPI0912570A2/pt
Publication of BRPI0912570B1 publication Critical patent/BRPI0912570B1/pt
Publication of BRPI0912570B8 publication Critical patent/BRPI0912570B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
BRPI0912570A 2008-05-07 2009-05-06 anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos BRPI0912570B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08103847.3 2008-05-07
EP08103847 2008-05-07
PCT/EP2009/055448 WO2009135861A2 (en) 2008-05-07 2009-05-06 Humanized antibodies against human interferon-alpha

Publications (3)

Publication Number Publication Date
BRPI0912570A2 BRPI0912570A2 (pt) 2016-04-26
BRPI0912570B1 BRPI0912570B1 (pt) 2021-04-06
BRPI0912570B8 true BRPI0912570B8 (pt) 2021-05-25

Family

ID=40901961

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912570A BRPI0912570B8 (pt) 2008-05-07 2009-05-06 anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos

Country Status (15)

Country Link
US (3) US8163885B2 (https=)
EP (1) EP2279207B1 (https=)
JP (1) JP5766598B2 (https=)
KR (1) KR101687032B1 (https=)
CN (1) CN102083859B (https=)
AU (1) AU2009245792B2 (https=)
BR (1) BRPI0912570B8 (https=)
CA (1) CA2722622C (https=)
ES (1) ES2549903T3 (https=)
IL (1) IL208979B (https=)
MX (1) MX2010012052A (https=)
RU (1) RU2532832C2 (https=)
TW (1) TWI453032B (https=)
WO (1) WO2009135861A2 (https=)
ZA (1) ZA201008748B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155831B (zh) 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
BR112013030242A2 (pt) * 2011-05-25 2016-12-06 Medimmune Llc método de tratamento de um distúrbio autoimune em um sujeito humano
WO2013034160A1 (en) * 2011-09-06 2013-03-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Methods for analyzing biological macromolecular complexes and use thereof
KR20150128849A (ko) 2013-03-15 2015-11-18 얀센 바이오테크 인코포레이티드 인터페론 알파 및 오메가 항체 길항제
JP6742237B2 (ja) * 2013-07-03 2020-08-19 イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ ヒト抗ｉｆｎ−アルファ抗体
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10689703B2 (en) * 2015-04-27 2020-06-23 National Jewish Health Methods of identifying and treating subjects having acute respiratory distress syndrome
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
JP2022527542A (ja) 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法
BR112022003163A2 (pt) * 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
CN112500476B (zh) * 2020-12-16 2024-02-23 南京基蛋生物医药有限公司 一种扩增鼠单抗重轻链基因序列的方法及其引物和筛选该引物的方法
CN116355079B (zh) * 2022-08-19 2023-12-26 上海迈科康生物科技有限公司 检测重组人轮状病毒vp8抗原（vp8 p[8]）的单克隆抗体及其应用
WO2025247924A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247918A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247917A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4824432A (en) 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4605394A (en) 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4362155A (en) 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
DE3211263A1 (de) 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
ES2133285T3 (es) 1991-04-17 1999-09-16 Medisup Int Nv Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
DK0601052T3 (da) 1991-08-30 1996-11-18 Genentech Inc Terapeutisk fremgangsmåde til behandling af IDDM
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
WO1998006431A2 (en) 1996-08-16 1998-02-19 Osther Kurt B Method for treating diabetes
US5902321A (en) 1997-07-25 1999-05-11 Innovasive Devices, Inc. Device and method for delivering a connector for surgically joining and securing flexible tissue repair members
US20030018174A1 (en) 1997-10-06 2003-01-23 Genentech, Inc. Monoclonal antibodies to IFNAR2
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
CN1454215B (zh) 1999-11-15 2013-01-02 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6660523B2 (en) 2000-09-21 2003-12-09 Schering Corporation Dendritic cells; methods
EP1351707B9 (en) 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
DE20100503U1 (de) 2001-01-12 2001-05-10 Josef Schiele oHG, 56651 Niederzissen Beschichtungsvorrichtung für ein langgestrecktes Werkstück
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
WO2003068801A2 (en) * 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
CN101056654A (zh) 2004-10-07 2007-10-17 苏黎士大学 用于预防和治疗银屑病的i型干扰素阻断剂
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CN101155831B (zh) * 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
JP5230022B2 (ja) * 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法

Also Published As

Publication number Publication date
KR20110042264A (ko) 2011-04-26
BRPI0912570B1 (pt) 2021-04-06
ES2549903T3 (es) 2015-11-03
CN102083859B (zh) 2014-09-17
JP5766598B2 (ja) 2015-08-19
US8361463B2 (en) 2013-01-29
WO2009135861A3 (en) 2010-01-28
CA2722622A1 (en) 2009-11-12
IL208979B (en) 2018-02-28
EP2279207A2 (en) 2011-02-02
CA2722622C (en) 2018-01-02
EP2279207B1 (en) 2015-09-09
HK1154251A1 (zh) 2012-04-13
JP2011519571A (ja) 2011-07-14
TWI453032B (zh) 2014-09-21
KR101687032B1 (ko) 2016-12-15
RU2010150105A (ru) 2012-06-20
AU2009245792A1 (en) 2009-11-12
US20120195888A1 (en) 2012-08-02
US8163885B2 (en) 2012-04-24
US20130101602A1 (en) 2013-04-25
IL208979A0 (en) 2011-01-31
BRPI0912570A2 (pt) 2016-04-26
CN102083859A (zh) 2011-06-01
ZA201008748B (en) 2013-02-27
TW200950807A (en) 2009-12-16
AU2009245792B2 (en) 2012-11-01
MX2010012052A (es) 2010-12-14
US20110213125A1 (en) 2011-09-01
RU2532832C2 (ru) 2014-11-10
WO2009135861A2 (en) 2009-11-12
US8658771B2 (en) 2014-02-25

Similar Documents

Publication Publication Date Title
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
UA109658C2 (xx) Антитіло проти cgrp
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BRPI0608281B8 (pt) anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
EA201100694A1 (ru) Антитело к cd38 человека и его применение
BR112016013338A2 (pt) anticorpo pd-1, fragmento de ligação do antígeno do mesmo e uso médico do mesmo
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ARGOS THERAPEUTICS , INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2826 DE 06-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.